A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)
Status:
Completed
Trial end date:
2019-02-04
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of tocilizumab compared with placebo in
participants with SSc across approximately 120 planned global study sites. The study will
consist of a 48-week, double-blind, placebo-controlled period followed by a 48-week
open-label treatment period. Participants will be assigned, in a 1:1 ratio, to double-blind
treatment with active tocilizumab or matching placebo. In the open-label period, eligible
participants from either arm may receive active tocilizumab.